Latest Tiziana Life Sciences News & Updates

See the latest news and media coverage for Tiziana Life Sciences. We track all announcements, press releases, and industry mentions in real time, all in one place.

Tiziana Life Sciences

Clinical-stage biopharmaceutical company developing immunotherapies for neurological and inflammatory conditions

tizianalifesciences.com

Headquarters: London, United Kingdom
Company type: Public company
Number of employees: 10–50

Last updated Today

Latest news about Tiziana Life Sciences

In short: Tiziana Life Sciences reported clinical progress for its lead drug foralumab and secured $17.6 million in funding while expanding its MS and AD trials.

Company announcements

June 15 Tiziana Life Sciences

Tiziana Life Sciences announces executive chairman's share purchase

Mr. Gabriele Cerrone bought 15,000 common shares at $1.11, increasing his stake to 34.89%.

May 21 Tiziana Life Sciences

Tiziana Life Sciences fully enrolls Phase 2 multiple sclerosis trial

The randomized, double-blind, placebo-controlled trial evaluates intranasal foralumab in 48 patients with non-active secondary progressive MS.

May 19 Tiziana Life Sciences

Tiziana announces positive clinical data for intranasal foralumab in na-SPMS

Patients showed encouraging stabilization of disability and meaningful fatigue improvements with no new safety signals.

May 14 Tiziana Life Sciences

Tiziana Life Sciences reports reduced brain inflammation in MSA patients

This is the third indication showing reduced inflammation on PET scans with intranasal foralumab, the first intranasal immune modulator in MSA trials.

Media coverage

June 15 Yahoo Finance

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab...

May 21 AP News

Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial

BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a...

May 20 Multiple Sclerosis News Today

Foralumab shows promise in nonactive SPMS, EAP data suggest

Foralumab may help slow disability progression and ease fatigue in people with nonactive SPMS, per data from an early access program.

May 19 Yahoo Finance

Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

Favourable trends seen in stability of disability and clinically meaningful improvements in fatigue. BOSTON, May 19, 2026 ...

Never miss news about Tiziana Life Sciences

Track Tiziana Life Sciences and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.